Obstet Med. 2025 Aug 19:1753495X251356377. doi: 10.1177/1753495X251356377. Online ahead of print.
ABSTRACT
BACKGROUND: Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.
METHODS: A literature search of Ovid MEDLINE and EMBASE for ‘hairy cell leukaemia’ and ‘Pregnancy’ was undertaken.
RESULTS: Thirteen cases were reviewed including three within our own institutions. Interferon-alpha was the most prominent treatment at varying doses in n = 3 (23%) patients. Other management included antenatal cladribine and rituximab, post-partum cladribine with and without rituximab, laparoscopic splenectomy and termination of pregnancy. 46.1% (n = 6) of patients birthed vaginally. Due to thrombocytopenia, there was a greater proportion of caesarean delivery under general anaesthetic and half of the cases documented bleeding complications.
CONCLUSION: Diagnosis and management of HCL in pregnancy is difficult. Women can be managed safely and outcome aims should be the same as non-pregnant patients.
PMID:40852641 | PMC:PMC12367712 | DOI:10.1177/1753495X251356377
